Abstract: A Janus G-C base as building block for a triazine based self-assembly of formula (I), a process for the preparation, and its application in developing supramolecular polymers, peptide nucleic acids (PNAs) and smart polymers thereof. A triazine based self-assembly of formula (I): wherein, ‘R’ is selected from the group comprising of linear or branched unsubstituted and substituted C1-C7 alkyl, unsubstituted and substituted aryl, unsubstituted and substituted natural amino acids which may be protected, linear or branched unsubstituted and substituted C1-C7 alcohols, or linear or branched unsubstituted and substituted C1-C7 amines.

Abstract: The present disclosure relates to system(s) and method(s) for data processing and visualization. The system is configured to enable processing and visually representing a dataset specified by a user. Initially, the system accepts a rule corresponding to at least one dimension associated with the dataset, wherein the rule is associated with a lower level of abstraction. When a rollup operation is performed along the specified dimension of the dataset for generating higher level graphical representation, the system is configured to preserve the rule associated with the dataset, regardless of any mathematical or logical cancellation of values due to the rollup operation and reflects the lower level details at a higher level of abstraction.

Abstract: Master BOM creation may include extracting BOM data from first and second BOMs, and determining which BOM extracted data is greater. If the first or second BOM is a CAD BOM and the other BOM is a non-CAD BOM, the CAD BOM and non-CAD BOMs may be respectively used as a first and a second source BOM data for a master BOM table. If the first and second BOMs are non-CAD BOMs, or both of the first and second BOMs are CAD BOMs, the greater and lesser of the first and second BOM extracted data may be respectively used as the first and as the second source BOM data. A master BOM may be created based on mapping of the master BOM table to the second source BOM data.

Abstract: The present disclosure relates to system(s) and method(s) for data processing and visualization. The system is configured to enable processing and visually representing a dataset specified by a user. Initially, the system accepts a rule corresponding to at least one dimension associated with the dataset, wherein the rule is associated with a lower level of abstraction. When a rollup operation is performed along the specified dimension of the dataset for generating higher level graphical representation, the system is configured to preserve the rule associated with the dataset, regardless of any mathematical or logical cancellation of values due to the rollup operation and reflects the lower level details at a higher level of abstraction.

Abstract: Master BOM creation may include extracting BOM data from first and second BOMs, and determining which BOM extracted data is greater. If the first or second BOM is a CAD BOM and the other BOM is a non-CAD BOM, the CAD BOM and non-CAD BOMs may be respectively used as a first and a second source BOM data for a master BOM table. If the first and second BOMs are non-CAD BOMs, or both of the first and second BOMs are CAD BOMs, the greater and lesser of the first and second BOM extracted data may be respectively used as the first and as the second source BOM data. A master BOM may be created based on mapping of the master BOM table to the second source BOM data.

Abstract: The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil.

Abstract: Master BOM creation may include extracting BOM data from first and second BOMs, and determining which BOM extracted data is greater. If the first or second BOM is a CAD BOM and the other BOM is a non-CAD BOM, the CAD BOM and non-CAD BOMs may be respectively used as a first and a second source BOM data for a master BOM table. If the first and second BOMs are non-CAD BOMs, or both of the first and second BOMs are CAD BOMs, the greater and lesser of the first and second BOM extracted data may be respectively used as the first and as the second source BOM data. A master BOM may be created based on mapping of the master BOM table to the second source BOM data.

Abstract: The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil.

Abstract: Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections.

Abstract: Master BOM creation may include extracting BOM data from first and second BOMs, and determining which BOM extracted data is greater. If the first or second BOM is a CAD BOM and the other BOM is a non-CAD BOM, the CAD BOM and non-CAD BOMs may be respectively used as a first and a second source BOM data for a master BOM table. If the first and second BOMs are non-CAD BOMs, or both of the first and second BOMs are CAD BOMs, the greater and lesser of the first and second BOM extracted data may be respectively used as the first and as the second source BOM data. A master BOM may be created based on mapping of the master BOM table to the second source BOM data.

Abstract: Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections.

Abstract: The present invention discloses an isolation and purification process for mycophenolic acid obtained from the fermentation process. Invention further discloses preparation of sodium salt of mycophenolic acid and mycophenolate mofetil from mycophenolic acid.

Abstract: Disclosed herein is an industrial preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an organic or inorganic base under neat or aqueous condition to form 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperazinyl]dibenzo[b,f]-[1,4]thiazepine. The quetiapine free base obtained is further converted to its hemi-fumarate salt.

Abstract: Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof.

Abstract: The present invention discloses novel processes for preparing optically active sulphoxide compounds of formula I by asymmetric oxidation of prochiral sulphide compounds of Formula II. More particularly, the invention discloses processes for preparation of optically active proton pump Inhibitors (PPIs) or their optically active precursor (=intermediate) compounds (Formula I) that can be converted into pharmaceutically useful PPIs.

Abstract: The present invention relates to a process for preparation of isotretinoin and more specifically, to a purification process for obtaining highly pure isotretinoin that is useful as a keratolytic agent, particularly useful for the treatment of acne. The process involves treating isotretinoin containing metal contamination and/or other impurities with a base in a suitable solvent to form a solution of isotretinoin, followed by adsorption, precipiation, and filtration or centrifugation.

Abstract: Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof.

Abstract: The present invention relates to a novel polymorphic form of atovaquone. More particularly, it relates to a novel crystalline form, that has improved solubility and other bulk characteristics suitable for pharmaceutical application. The present invention also relates to processes for preparing a new polymorphic form of atovaquone and its use in industry.

Abstract: A one-pot industrial process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one of Formula-(I) from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one of Formula-(IV) involves reaction of Formula (IV) with HNR1R2 salt and paraformaldehyde, where R1,R2 are independently alkyl groups or together forms a cyclic alkyl group, in a solvent system of acetic acid and hydrocarbon solvent to form a crude mixture of intermediate compounds of Formula (III) and (VIII), which is converted to ondansetron (Formula (I)) without isolation by reaction with 2methyimidazole in a suitable solvent system in the same pot.

Abstract: The present invention discloses selective and complete reduction of pyridine ring in a biaryl system comprising ?-substituted or non-substituted benzene ring and relates more specifically, not exclusively, for the manufacture of methylphenidate, which is used for treatment of Attention Deficit Hyperactive Disorder (ADHD) and also acts as central nervous system stimulant, by using palladium/C in a solvent such as C1-C4 alcohols in presence of molar quantities of organic and/or inorganic acids.